<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1692-7273</journal-id>
<journal-title><![CDATA[Revista Ciencias de la Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Cienc. Salud]]></abbrev-journal-title>
<issn>1692-7273</issn>
<publisher>
<publisher-name><![CDATA[Editorial Universidad del Rosario]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1692-72732017000300325</article-id>
<article-id pub-id-type="doi">10.12804/revistas.urosario.edu.co/revsalud/a.6116</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Validación de la escala abreviada de síntomas en pacientes con neoplasias mieloproliferativas (MPN-SAF-TSS): evaluación en pacientes colombianos]]></article-title>
<article-title xml:lang="en"><![CDATA[Validation of the Abbreviated Symptom Scale for Patients with Myeloproliferative Neoplasm (MPN-SAF-TSS): Evaluation for Colombian Patients]]></article-title>
<article-title xml:lang="pt"><![CDATA[Validação da Escala Abreviada de Sintomas em Pacientes com Neoplasias Mieloproliferativas (MPN-SAF-TSS): Avaliação em Pacientes Colombianos]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lozano]]></surname>
<given-names><![CDATA[Teófilo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Wiesner]]></surname>
<given-names><![CDATA[Carolina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mesa]]></surname>
<given-names><![CDATA[Rubén]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Robyn]]></surname>
<given-names><![CDATA[Marie-Emanuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Suárez]]></surname>
<given-names><![CDATA[Martha]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salguero]]></surname>
<given-names><![CDATA[Edgar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,CIIC Consultores SAS  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Mayo Clinic Cancer Center Division of Hematology &amp; Medical Oncology ]]></institution>
<addr-line><![CDATA[Scottsdale Arizona]]></addr-line>
<country>United States of America</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>15</volume>
<numero>3</numero>
<fpage>325</fpage>
<lpage>334</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S1692-72732017000300325&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S1692-72732017000300325&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S1692-72732017000300325&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo:  Validar en Colombia la escala abreviada de síntomas representativos de neoplasias mieloproliferativas para su posterior uso en investigación y aplicación en el ámbito clínico.  Materiales y métodos:  Se realizó la adaptación transcultural de la escala MPN-SAF-TSS (por sus siglas en inglés: Mieloproliferative Neoplasm Symptom Assesment Form-Total Sympton Score) a español y al contexto colombiano, con análisis estadísticos de validez y confiabilidad con un tamaño de muestra determinado para cada propiedad psicométrica.  Resultados:  Con base en las propiedades psicométricas se logró verificar la confiabilidad y la estructura interna de la escala con alfa de Cronbach de 0,8552, lo que denota una buena consistencia interna; se obtuvo un coeficiente de correlación de concordancia de Lin de 0,765 que muestra una buena confiabilidad. El análisis factorial mostró múltiples valores de coeficiente de correlación por encima de 0,3, lo que indica que las variables de la escala miden factores comunes; la validez de criterio concurrente determina que la escala mide lo que debe medir con un adecuado coeficiente de correlación de Spearman de -0,71 y -0,73 al confrontarla con las escalas FACIT-Fatigue y Fact-Lym respectivamente.  Conclusión:  La escala MPN-SAF-TSS adaptada a español y al contexto colombiano es un instrumento válido para la evaluación de síntomas en pacientes con neoplasias mieloproliferativas y puede ser utilizado en la práctica clínica o en estudios clínicos por sus adecuadas propiedades psicométricas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective:  To validate in Colombia the abbreviated scale of representative symptoms of myeloproliferative neoplasms, for further use in research and for application in the clinical setting.  Materials and methods:  A cross-cultural adaptation of the MPN-SAF TSS-scale (mieloproliferative neoplasm symptom assessment form total symptom score) to Colombian Spanish using statistical validity and reliability analysis with a specific sample size for each psychometric property.  Results.  Based on the psychometric properties, the verification of reliability and internal structure with a Cronbach's alpha scale of 0.8552 was achieved, denoting good internal consistency. A Lin's concordance correlation coefficient of 0.765 was obtained, showing good reliability; factor analysis showed multiple correlation coefficient values above 0.3, indicating that the scale variables measure common factors. Concurrent validity determines that the scale measures what it should measure with an adequate Spearman correlation coefficient of -0.71 and -0.73 when confronted with the FACIT-Fatigue and Fact-Lym scales, respectively.  Conclusion:  The MPN-SAF-TSS scale adapted to Colombian Spanish is a valid assessment instrument for symptoms in patients with myeloproliferative neoplasms and can be used in clinical practice or trials due to its adequate psychometric properties.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Objetivo:  Validar na Colômbia, a escala abreviada de sintomas representativos de neoplasias mielo-proliferativas, para u seu posterior uso em investigação e a sua aplicação no âmbito clínico.  Materiais e métodos:  Realizou-se a adaptação transcultural da escala MPN-SAF-TSS (pelas suas siglas em inglês mieloproliferative neoplasm symptom assesment form total sympton score) ao espanhol colombiano, com análises estadísticas de validez e confiabilidade com um tamanho de amostra determinado para cada propriedade psicométrica.  Resultados:  Com base nas propriedades psicomé-tricas conseguiu-se verificar a confiabilidade e a estrutura interna da escala com alfa de Cronbach de 0,8552, o que denota uma boa consistência interna; se obteve um coeficiente de correlação de concordância de Lin de 0,765 mostrando uma boa confiabilidade; a análise fatorial mostrou múltiplos valores de coeficiente de correlação por acima de 0.3 indicando que as variáveis da escala medem fatores comuns, a validez de critério concorrente determina que a escala mede o que deve medir, com um adequado coeficiente de correlação de Spearman de -0,71 e -0,73 ao confrontá-la com as escalas FACIT-Fatigue e Fact-Lym respectivamente.  Conclusão:  A escala MPN-SAF TSS adaptada ao espanhol colombiano, é um instrumento válido para a avaliação de sintomas em pacientes com neoplasias mieloproliferativas e pode ser utilizado na prática clínica ou em estudos clínicos pelas suas adequadas propriedades psicométricas.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Estudio de validación]]></kwd>
<kwd lng="es"><![CDATA[trastornos mieloproliferativos]]></kwd>
<kwd lng="es"><![CDATA[evaluación de síntomas]]></kwd>
<kwd lng="es"><![CDATA[calidad de vida]]></kwd>
<kwd lng="es"><![CDATA[MPN-SAF-TSS]]></kwd>
<kwd lng="en"><![CDATA[Validation study]]></kwd>
<kwd lng="en"><![CDATA[myeloproliferative disorders]]></kwd>
<kwd lng="en"><![CDATA[symptom assessment]]></kwd>
<kwd lng="en"><![CDATA[quality of life]]></kwd>
<kwd lng="en"><![CDATA[MPN-SAF-TSS]]></kwd>
<kwd lng="pt"><![CDATA[Estudo de validação]]></kwd>
<kwd lng="pt"><![CDATA[transtornos mieloproliferativos]]></kwd>
<kwd lng="pt"><![CDATA[avaliação de sintomas]]></kwd>
<kwd lng="pt"><![CDATA[qualidade de vida]]></kwd>
<kwd lng="pt"><![CDATA[MPN-SAF-TSS]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pardanani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gotlib]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Jamieson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cortes]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Talpaz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Stone]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2011</year>
<volume>29</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>789-96</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mesa]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Kantarjian]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tefferi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dueck]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Vaddi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCBO18424) clinical trial.]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2011</year>
<volume>117</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>4869-77</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mesa]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Niblack]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wadleigh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Verstovsek]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Camoriano]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Barnes]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The burden of fatigue and quality of life in myeloproliferative disorders (MPDS): An international Internet-based survey of 1179 MPD patients]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2007</year>
<volume>109</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>68-76</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mesa]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Schwager]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Radia]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cheville]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hussein]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Niblack]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Myelofibrosis Symptom Assessment Form MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis]]></article-title>
<source><![CDATA[Leuk Res]]></source>
<year>2009</year>
<volume>33</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1199-203</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scherber]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dueck]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Johansson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Barbui]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Barosi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Vannucchi]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2011</year>
<volume>118</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>401-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Emanuel]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Dueck]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Geyer]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Kiladjian]]></surname>
<given-names><![CDATA[J-J]]></given-names>
</name>
<name>
<surname><![CDATA[Slot]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zweegman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNS]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2012</year>
<volume>30</volume>
<numero>33</numero>
<issue>33</issue>
<page-range>4098-103</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Emanuel RM]]></surname>
<given-names><![CDATA[Dueck AC]]></given-names>
</name>
<name>
<surname><![CDATA[Geyer HL]]></surname>
<given-names><![CDATA[Kiladjian J-J]]></given-names>
</name>
<name>
<surname><![CDATA[Slot S]]></surname>
<given-names><![CDATA[Zweegman S]]></given-names>
</name>
<name>
<surname><![CDATA[et. ál]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myeloproliferative (MPN) symptom burden response thresholds: Assessment of MPN-SAF TSS quartiles as potential markers of symptom response]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2013</year>
<volume>122</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>4067</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montero]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[León]]></surname>
<given-names><![CDATA[OG]]></given-names>
</name>
</person-group>
<source><![CDATA[Sistema de clasificación del método en los informes de investigación en Psicología 1]]></source>
<year>2005</year>
<numero>5</numero>
<issue>5</issue>
<page-range>115-27</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<collab>R Core Team</collab>
<source><![CDATA[R: A language and environment for statistical computing]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Vienna, Austria ]]></publisher-loc>
<publisher-name><![CDATA[R Foundation for Statistical Computing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Norman]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Streiner]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
</person-group>
<source><![CDATA[Bioestadística]]></source>
<year>1996</year>
<publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Mosby Doyma Libros]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Donner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Eliasziw]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sample size requirements for reliability studies]]></article-title>
<source><![CDATA[Stat Med]]></source>
<year>1987</year>
<numero>6</numero>
<issue>6</issue>
<page-range>441-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Swerdlink]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<source><![CDATA[Pruebas y evaluación psicológicas]]></source>
<year>2001</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Mc Graw Hill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lawrence]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A concordance correlation coefficient to evaluate reproducibility]]></article-title>
<source><![CDATA[Biometrics]]></source>
<year>1989</year>
<volume>45</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>255-68</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salkind]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Métodos de investigación]]></source>
<year>1999</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Prentice Hall]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Le]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[La unidimensionalidad de un instrumento de medición: Perspectiva Factorial]]></source>
<year>2005</year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mitra]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kaye]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Piecoro]]></surname>
<given-names><![CDATA[LT]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Reith]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mughal]]></surname>
<given-names><![CDATA[TI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Symptom burden and splenomegaly in patients with myelofibrosis in the United States: A retrospective medical record review.]]></article-title>
<source><![CDATA[Cancer Med]]></source>
<year>2013</year>
<volume>2</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>889-98</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
